![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 33, 23135-23143, August 13, 1999
,
,
,
, and
§¶
From the
Department of Chemistry and Biochemistry,
University of Windsor, Windsor, Ontario N9B 3P4, Canada and the
§ Division of Clinical Biochemistry, Laboratory Medicine and
Pathobiology, Hospital for Sick Children, University of Toronto,
Toronto, Ontario M5G 1X8, Canada
| |
ABSTRACT |
|---|
|
|
|---|
It has been well established that the biogenesis
of apoB is mediated co-translationally by the cytosolic proteasome.
Here, however, we investigated the role of both the cytosolic
proteasome as well as non-proteasome-mediated degradation systems in
the post-translational degradation of apoB. In pulse-chase
labeling experiments, co-translational (0-h chase) apoB degradation in both intact and permeabilized cells was sensitive to proteasome inhibitors. Interestingly, turnover of apoB in intact cells over a 2-h
chase was partially inhibitable by lactacystin, thus suggesting a role
for the cytosolic proteasome in the post-translational degradation of
apoB. In permeabilized cells, however, there was no post-translational
protection of apoB by lactacystin. Further investigations of
proteasomal activity in HepG2 cells revealed that, following
permeabilization, there was a dramatic loss of the 20 S proteasomal
subunits, and consequently the cells exhibited no detectable
lactacystin-inhibitable activity. Thus, apoB fragmentation and the
generation of the 70-kDa apoB degradation fragment, characteristic of
permeabilized cells, continued to occur in these cells despite the
absence of functional cytosolic proteasome. Similar results were
observed when we used a derivative of lactacystin, clastolactacystin Hepatic apolipoprotein B100
(apoB)1 secretion appears to
be regulated post-transcriptionally (1-4). More specifically,
efficient translocation of newly synthesized apoB molecules across the
membrane of the endoplasmic reticulum (ER) is believed to be an
important event that contributes to the formation of secretion
competent apoB-containing lipoproteins (5-8). Inefficient
translocation has been suggested to lead to the formation of a pool of
membrane-associated apoB that becomes ubiquitinated (12-20, 22) and
ultimately destined for intracellular degradation (6, 8-11). It is
evident that co-translational degradation of membrane-associated apoB
is mediated by the cytosolic proteasome based on its sensitivity to
proteasome inhibitors such as ALLN, lactacystin, and MG132 (9,
12-22).
The involvement of the proteasome in degradation of apoB raises a
number of intriguing questions. Clearly, the proteasome is involved in
co-translational degradation of membrane-associated apoB, which is
expected to have cytosolic exposure. However, recent evidence has
suggested that the proteasome may also be involved in the
post-translational degradation of apoB (19, 21, 22). Post-translational
degradation of apoB in HepG2 cells has generally been thought to occur
in the ER or a closely associated compartment (5, 16, 23, 24), although
studies in rat hepatocytes have suggested that degradation of apoB may
occur in post-ER compartments (25-27). It is speculated that a number
of degradation systems may be involved in the intracellular turnover of
apoB. Degradation of apoB appears to generate distinct proteolytic
intermediates in both intact (9, 28) and permeabilized HepG2 cells
(16). In permeabilized cells, apoB degradation occurs by a temperature- and pH-dependent and ALLN-sensitive cysteine protease in an
ER-related compartment (16), resulting in the generation of an abundant N-terminal 70-kDa fragment, which can be detected in the lumen of the
secretory pathway (16, 29, 30). In addition, we have reported that the
apoB associated with luminal lipoproteins is also degraded
post-translationally by an ALLN-sensitive degradation mechanism and
could be rescued from degradation by cytosolic factors and metabolic
energy, perhaps by inducing transport of apoB out of the degradation
compartment (30). Furthermore, Wu et al. (14) have reported
a two-site model for the degradation of apoB in HepG2 cells, suggesting
that after the initial rapid degradation process, apoB that is fully
translocated into the ER lumen can still undergo degradation via a
second proteolytic system that is ALLN-resistant but sensitive to
DTT.
In the present report, we used both intact and permeabilized HepG2 cell
systems (16, 29, 30) to study the role of the cytosolic proteasome in
post-translational apoB degradation. We report that post-translational
degradation of apoB in intact cells is partially sensitive to
proteasomal inhibitors, thus suggesting the involvement of the
proteasome. Interestingly, however, we found that permeabilization of
HepG2 cells results in the loss of proteasome function as determined by
the loss of both lactacystin-inhibitable proteasome activity as well as
proteasomal subunits. Permeabilized cells that are largely devoid of
the cytosolic proteasome appear to continue to degrade apoB, generating
specific fragments, including the 70-kDa fragment, via a
lactacystin-insensitive process. Hence, the permeabilized cell model
provides a system to study post-translational apoB fragmentation in the
absence of the functional cytosolic proteasome. Moreover, the data from
the permeabilized cell system suggests that post-translational turnover
of luminal apoB may also involve nonproteasomal degradation systems.
Materials--
HepG2 cells (ATCC HB 8065) were obtained from the
American Type Culture Collection. Fetal bovine serum (certified grade)
and cell culture media were from Life Technologies (Toronto). Digitonin of a higher purity (100%) was obtained from Calbiochem. Rabbit anti-rat 20 S proteasome antibody was a kind gift from Walter Ward
(Texas), and the microsomal triglyceride transfer protein (MTP)
inhibitor BMS-197636 was provided by Dr. David Gordon (Bristol Meyers
Squibb, Princeton, NJ). Lactacystin was purchased from Dr. E. J. Corey (Harvard University).
Cell Culture--
Cultures of HepG2 were maintained in an
Metabolic Labeling of Intact Cells, Permeabilization, and
Determination of ApoB Degradation--
Nearly confluent HepG2 cultures
were incubated with methionine/cysteine-free MEM for 120 min,
pulse-labeled (15-120 min; see figure legends) with 100 µCi/ml
35S protein labeling mix (Pro-MixTM), washed
three times, and chased for various chase periods (10-120 min) in
culture medium supplemented with 10 mM methionine and 2 mM cysteine. At the end of each chase period, the medium
was removed, and the cells were washed once with phosphate-buffered saline. The cells were harvested in a solubilization buffer
(phosphate-buffered saline containing 1% Nonidet P-40, 1%
deoxycholate, 5 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 100 kallikrein-inactivating units/ml Trasylol, 0.1 mM
leupeptin, 0.5 µM ALLN). Cell extracts and media were
centrifuged in a microcentrifuge at 14,000 rpm for 10 min, and the
supernatant was subjected to immunoprecipitation.
To examine apoB degradation in permeabilized cells, intact cells chased
for 10 min were washed and incubated for 10 min at room temperature in
cytoskeletal (CSK) buffer (0.3 M sucrose, 0.1 M
KCl, 2.5 mM MgCl2, 1 mM sodium-free
EDTA, 10 mM PIPES, pH 6.8) containing 50 µg/ml digitonin.
Permeabilized cells were washed three times in CSK buffer and were then
incubated in CSK buffer under various conditions as described in the
figure legends. The cells were harvested in solubilization buffer, and
the cell extracts were subjected to immunoprecipitation.
Microsomal Triglyceride Transfer Protein Inhibitor
Studies--
Nearly confluent HepG2 cells grown in six-well plates
were incubated for 1 h in methionine/cysteine-free medium
containing 0-50 nM MTP inhibitor (BMS-197636) and 20 µg/ml ALLN. Following the preincubation, cells were briefly pulsed
with 35S protein labeling mix and chased for 10 min in
Fluorescein Isothiocyanate-labeled Casein Assay for Proteasome
Activity--
Cells were incubated in complete Chemiluminescent Immunoblotting for the 20 S Proteasome
Subunits--
Cell samples from the proteasome assay described above
were also subjected to chemiluminescent immunoblotting for the 20 S proteasome subunits. Samples were subjected to SDS-PAGE using a 10%
polyacrylamide minigel (8 × 5 cm). Following SDS-PAGE, the proteins were transferred electrophoretically overnight at 4 °C onto
nitrocellulose membranes using a Bio-Rad wet transfer system. The
membranes were blocked with a 5% solution of fat-free dry milk powder
and then incubated for 1 h in a 1:1000 dilution of the primary
antibody, rabbit anti-rat 20 S proteasome, which also cross-reacts with
the human proteasomal subunits. After several washes, the membranes
were incubated for 1 h in a 1:8000 dilution of the secondary
antibody conjugated to peroxidase solution. Membranes were then
incubated in an ECL detection reagent for 60 s and exposed to
Hyperfilm. Films were developed, and quantitative analysis was
performed using an imaging densitometer.
Immunoprecipitation, SDS-PAGE, and
Fluorography--
Immunoprecipitation was performed as described
previously (16). Immunoprecipitates were washed with wash buffer (10 mM Tris-HCl, pH 7.4, 2 mM EDTA, 0.1% SDS, 1%
Triton X-100) and were prepared for SDS-PAGE by suspension and boiling
in 100 µl of electrophoresis sample buffer. SDS-PAGE was performed
essentially as described (33). The gels were fixed, stained, and
fluorographed by incubation in Amplify. The gels were dried and exposed
to Dupont autoradiographic film at Effects of Lactacystin on the Co- and Post-translational
Degradation of ApoB in Intact Cells--
In an attempt to distinguish
the role of the proteasome in co- and post-translational degradation of
apoB, intact HepG2 cells were first pretreated with the proteasome
inhibitor, lactacystin, and then pulsed and chased over a 120-min
period. Lactacystin pretreatment of cells 30 min before the pulse
induced a significant increase in the amount of apoB accumulated at
0 h (2.6-fold increase over control), which remained high during
the 120-min chase (Fig. 1A).
To assess post-translational sensitivity to lactacystin, cells were
chased for 60 and 120 min in the presence and absence of the inhibitor
(Fig. 1B). In control cells, 53% of apoB was recovered
after a 60-min chase, whereas in lactacystin-treated cells 78% was
recovered. This difference was also observed after 120 min of chase
time with only a 48% recovery of apoB in control cells as opposed to a
76% recovery in lactacystin-treated cells. Hence, even after a 2-h
chase, degradation of apoB remained sensitive to lactacystin, thus
suggesting a role for the proteasome after translation of apoB.
Nevertheless, there was still an approximate 24% loss in
35S-labeled apoB during the chase of lactacystin-treated
cells, despite the presence of the inhibitor (Fig. 1B).
Effect of Lactacystin on Post-translational Fragmentation of ApoB
in Permeabilized Cells--
We used a permeabilized cell system in
conjunction with lactacystin to further examine the role of the
proteasome in the specific fragmentation of apoB and the generation of
the 70-kDa degradation fragment. Intact HepG2 cells were briefly pulsed
and chased and then permeabilized with 50 µg/ml digitonin. Under
these conditions, permeabilized cells do not possess protein synthesis
activity nor secrete proteins, but they retain the capability to
intracellularly degrade proteins including apoB. To monitor degradation
of the newly synthesized radiolabeled apoB pool, permeabilized cells were incubated in CSK buffer with and without lactacystin for 120 min.
The inhibitory function of lactacystin demonstrates a lag period (34);
thus, the addition of this drug 30 min before the pulse was necessary
to ensure that the inhibitor was present in its active form during the
pulse. Fig. 2, A and
B, shows that a significantly higher level of apoB was
present in lactacystin-treated permeabilized cells at zero time, in
comparison with cells not treated with lactacystin (3.4-fold increase
over control). Over the 120-min chase following permeabilization, a
major proportion of 35S-labeled apoB was degraded in both
control and lactacystin-pretreated cells (Fig. 2B).
Furthermore, in the presence of lactacystin, there was a dramatic
accumulation of the major degradation intermediates of apoB, including
the 70-kDa fragment (Fig. 2A). Enhanced generation of the
fragment appeared to result from a greater pool of
35S-labeled apoB100 at zero time in lactacystin-pretreated
cells.
We also examined the possibility that the digitonin treatment of the
cells may have resulted in the leakage of apoB from the secretory
pathway (ER-Golgi system) into the CSK buffer. After permeabilization,
we collected both the cells and CSK buffer at 0 h (CSK plus
digitonin) and at different periods of chase and probed for apoB. Two
representative experiments are shown. The amount of intact apoB in
permeabilized cells declined over the chase period, concomitant with an
increase in the accumulation of the 70-kDa fragment in the cells (Fig.
3). Little or no radiolabeled full-length
apoB or the 70-kDa fragment could be detected in the CSK buffer at
different chase times, and the amount detected was negligible compared
with total immunoprecipitable apoB (Fig. 3). There was also no
continued accumulation of the intact apoB or its 70-kDa fragment in the
CSK buffer over time. Overall, the data suggest that there is minimal
nonspecific loss of radiolabeled apoB following permeabilization of
HepG2 cells and that temporal disappearance of intact apoB in
permeabilized cells can be accounted for by intracellular degradation
rather than cell leakage.
Comparison of Proteasomal Activity in both Intact and Permeabilized
Cells--
In order to assess any effects permeabilization may have on
the proteasomal activity of HepG2 cells, we measured protease activity
of cell lysates prepared from intact and permeabilized HepG2 cells that
were pretreated with and without lactacystin. In this particular assay,
all detectable proteolytic activity was measured using fluorescein
isothiocyanate-labeled casein as the proteolytic substrate. We
initially examined the difference in total proteolytic activity between
intact and permeabilized cells without lactacystin treatment and found
that there was a decrease in the amount of proteolytic activity after
permeabilization of the cells (0.23 ± 0.16 fluorescent units
detected in permeabilized cells in comparison with 5.97 ± 1.2 fluorescent units detected in intact cells) (Fig.
4A). In the presence of
lactacystin, there was a considerable decrease in detectable
proteolytic activity in intact cells (lactacystin-inhibitable activity,
2.84 ± 0.75 fluorescent units) (Fig. 4B). The loss in
proteolytic activity was considered to be proteasomal in nature, since
the difference between the two conditions was the presence of the
proteasomal inhibitor, lactacystin. We then examined permeabilized
cells and found no detectable lactacystin-inhibitable proteolytic
activity (Fig. 4B). The absence of any appreciable
lactacystin-inhibitable protease activity in permeabilized cells
suggests significant loss of proteasomal activity in these cells.
Detection of the 20 S Proteasomal Subunits in Intact and
Permeabilized Cells--
To assess whether the loss of proteasomal
activity following permeabilization was due to the loss of proteasome
subunits, we immunblotted intact and permeabilized cells for several of the subunits of the 20 S proteasome that have both structural and
functional roles in the proteasome complex. Immunoblotting of intact
HepG2 cell lysates with the polyclonal antibody revealed several of the
20 S subunits ranging in size from 25 to 35 kDa (Fig.
5A). However, immunoblotting
of permeabilized cell lysates revealed a dramatic reduction in the
detection of the 20 S subunits (~68% reduction compared with intact
cells), thus indicating a significant loss of the cytosolic proteasome
upon permeabilization (Fig. 5B). Furthermore, a significant
amount of proteasomal subunits was detected in CSK plus digitonin
buffer used in the permeabilization of the cells (~49% detected in
comparison with intact cells) (Fig. 5B).
Differential Sensitivity of ApoB Degradation in Permeabilized Cells
to Lactacystin, Clastolactacystin
We also tested the inhibitory effect of clastolactacystin Effect of MTP Inhibition and DTT on the Degradation of ApoB in
Permeabilized HepG2 Cells--
In an attempt to further characterize
the degradation of apoB in permeabilized HepG2 cells, we used an
inhibitor of MTP. Fig. 7A
shows the immunoprecipitable apoB isolated from permeabilized HepG2
cells following 0 and 2 h in CSK with and without the MTP inhibitor. In control cells, the majority of apoB present at 0 h
is degraded after the 2-h incubation in CSK (~83% degradation) and
is accompanied by the generation of the 70-kDa apoB fragment. Quite
surprisingly, less degradation of apoB was observed in MTP inhibitor-treated cells after a 2-h incubation (~45% degradation) in
comparison with control cells. The amount of intact apoB remaining after 2 h was significantly higher in cells treated with the
inhibitor (Fig. 7B) despite a considerable decrease in the
amount of apoB present at 0 h in MTP inhibitor-treated cells. In
addition, although not statistically significant, the generation of the
70-kDa fragment was also reduced in MTP inhibitor-treated cells (Fig.
7C).
In order to confirm the above observations, the experiment in
permeabilized cells was conducted using concentrations of the MTP
inhibitor ranging from 1 to 50 nM. Fig.
8A shows the percentage of
apoB remaining in control cells and MTP inhibitor-treated cells following a 2-h incubation period. There was no significant difference between the percentage of apoB remaining in control cells and cells
treated with the lowest concentration (1 nM) of the
inhibitor; however, with increasing concentrations of the inhibitor (10 and 50 nM), the percentage of apoB remaining also increased
(Fig. 8A). An inverse relationship was observed between the
level of inhibition of MTP and the susceptibility of apoB to
fragmentation in permeabilized cells, with the greatest amount of
70-kDa fragment detected in control cells (Fig. 8B).
The reducing agent DTT was also employed to examine whether or not
modulation of the redox state of the ER could affect the fragmentation
of apoB in permeabilized cells. Fig. 9
shows the alteration in the apoB fragmentation pattern observed in
DTT-treated cells compared with control cells. ApoB degradation
occurred in DTT-treated without the generation of the 70-kDa apoB
fragment.
Intracellular degradation of apoB is very active in HepG2 cells,
resulting in the secretion of only a small fraction of the total apoB
synthesized. The intracellular mechanisms responsible for degradation
of nascent apoB chains have been the subject of intense investigation
in the past few years (5, 6, 9-30, 35). Many recent reports have shown
evidence for the involvement of the proteasome in the co-translational
degradation of apoB in HepG2 cells (12-22). This evidence includes the
sensitivity of apoB degradation to various proteasome inhibitors (12,
13, 15, 18-22), the detection of ubiquitinated apoB (12, 18-20, 22),
and more recently the association of ubiquitinated apoB with the Sec61
complex of the translocon (18, 19). Our data in the present report
suggest the involvement of the cytosolic proteasome not only in
co-translational apoB degradation but also in its post-translational
turnover. Recent reports (19, 22) have also provided evidence for the
involvement of the cytosolic proteasome in the post-translational
degradation of apoB. Laio et al. (22) have suggested that
following translation and translocation in the ER, apoB may be targeted
for proteasome-mediated degradation via retrograde translocation from
the lumen of the ER to the cytosol. On the other hand, Mitchell
et al. (19) have argued against complete retrograde
translocation of apoB from the lumen of the ER to the cytosol and
instead have shown that, following translocation, apoB may be
ubiquitinated and remain associated with the Sec61 To further explore the role of the proteasome in the post-translational
degradation of apoB, we used a permeabilized cell system in conjunction
with the proteasome inhibitor, lactacystin. Our observations revealed
that although lactacystin inhibited co-translational degradation of
apoB, post-translational fragmentation of apoB, which normally results
in the generation of degradation intermediates, was not inhibited by
lactacystin. Furthermore, the results from proteasome assays indicated
that, in contrast to intact cells, permeabilized cells contained no
detectable lactacystin-inhibitable protease activity, suggesting the
lack of proteasomal activity in these cells. This lack of proteasomal
activity was determined to be a result of a major loss of both
functional and structural 20 S proteasomal subunits following
permeabilization of these cells. It is important to note that we cannot
exclude the possibility of some ER-bound proteasome remaining
associated with permeabilized cells. However, our results showing the
absence of proteasomal activity in permeabilized cells and the lack of
sensitivity to lactacystin, even after the addition of cytosol, appear
to rule out the possibility that a potential membrane-associated
proteasome pool is responsible for the specific fragmentation of
apoB.
To explore the potential role of the proteasome in the generation of
the 70-kDa fragment, we used two potent proteasome inhibitors, lactacystin and clastolactacystin To further characterize the degradative process operating in
permeabilized cells, we examined the effects of inhibiting MTP on the
generation of the 70-kDa fragment in permeabilized cells. Since
inhibition of MTP increases the pool of secretion-incompetent apoB, we
explored the role of this alternate degradation system on this pool of
apoB (30). The results established an inverse relationship between the
concentration of the MTP inhibitor and the generation of the 70-kDa
fragment, thus suggesting that the pool of apoB accumulated in the
presence of MTP inhibitor was not accessible to the degradation
machinery responsible for generation of the fragment. Instead, it seems
likely that a large percentage of this pool of apoB is destined for
co-translational degradation via the proteasome on the cytosolic side
of the ER membrane. This hypothesis is also in accordance with the
findings of Benoist and Grand-Perret (15), suggesting that inhibition
of MTP activity may induce co-translocational degradation of apoB by
the proteasome. This in turn would suggest that less apoB is localized
to the ER lumen, thus leading to a decrease in the generation of the 70-kDa fragment.
Studies were also performed with the reducing agent DTT, and results
revealed that in the presence of DTT there was an acceleration in the
post-translational degradation of apoB in permeabilized HepG2 cells.
Previous work in our laboratory (44) as well as others (45) has shown
that disruption of disulfide bond formation within the apoB molecule
can inhibit the secretion of apoB and induce its intracellular
degradation. The observation that apoB degradation in DTT-treated cells
occurred without the generation of the 70-kDa apoB fragment suggests
that the degradation pathway may be altered in the presence of DTT. We
hypothesize that the presence of DTT induces conformational changes in
apoB and stimulates its rapid co-translational degradation, thus not
allowing for delivery of full-length substrate to a second degradative pathway.
There is precedence for the involvement of proteases functioning in
conjunction with the proteasome in the regulated degradation of
proteins in eukaryotic cells (46, 47). Our data suggest that in intact
cells, if newly synthesized apoB chains are rescued from
co-translational proteasome-mediated degradation, they are still
sensitive to the proteasome following translation and translocation (based on data in intact cells) and other nonproteasomal degradative system(s) (based on data in permeabilized and intact cells). It is
likely that there is an association between proteasomal and nonproteasomal degradation systems. This is particularly apparent from
our observation that inhibition of co-translational proteasomal degradation by pretreatment with lactacystin increases the abundance of
the 70-kDa fragment apparently by providing more substrate for the
post-translational non-proteasome-mediated fragmentation process.
Hence, further studies are clearly needed to elucidate the complex
interrelationship between proteasomal and nonproteasomal degradative
systems that act to destabilize the secretion incompetent apoB intracellularly.
-lactone, which represents the active species of the inhibitor. Interestingly, however, the abundance of the 70-kDa fragment could be
modulated by the microsomal triglyceride transfer protein inhibitor, BMS-197636, as well as by pretreatment of the permeabilized cells with
dithiothreitol. These data thus suggest that although the cytosolic
proteasome appears to be involved in the post-translational turnover of
apoB in intact cells, the specific post-translational fragmentation of
apoB generating the 70-kDa fragment observed in permeabilized cells
occurs independent of the cytosolic proteasome.
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-modification of Eagle's minimal essential medium (
-MEM)
containing 10% fetal bovine serum. Cells were grown in 35-, 60-, or
100-mm dishes at 37 °C, 5% CO2 in complete medium
(
-MEM, 10% fetal bovine serum) (31). Cultures were allowed to reach
75-80% confluence before experiments were carried out.
-MEM plus 10 mM L-methionine. Cells were
washed three times in CSK buffer and permeabilized with digitonin (50 µg/ml, 10 min). At this point (0 time), control and treated cells
were collected, and the remaining cells were incubated in CSK buffer
supplemented with or without the MTP inhibitor. After the first hour of
incubation, CSK buffer was removed, the cells were washed twice, and
fresh CSK was added for the remaining 2 h. The cells were
harvested in solubilization buffer, and the cell extracts were
subjected to immunoprecipitation.
-MEM in the presence
and absence of 25 µM lactacystin for 1 h. Some cells
were then washed in CSK and permeabilized as described above, and other
cells were left intact. Both intact and permeabilized cells were
collected in phosphate-buffered saline in the presence of 0.1% Triton
X-100 and homogenized in a Dounce glass homogenizer. Cell homogenates were centrifuged in a microcentrifuge at 14,000 rpm for 10 min, and the
supernatant was subjected to protease assays. The protease assays were
performed in 1.5-ml centrifuge tubes according to Twining (32) with
modifications to assess proteasomal activity. To each reaction tube the
following components were added: 20 µl of the respective sample, 25 µl of a 100 mM Tris, pH 7.8, buffer, 5 µl of 5 mg/ml
fluorescein isothiocyanate-labeled casein, and 5 µl of 250 µM lactacystin only to those samples already pretreated with lactacystin. The reaction was then carried out at 37 °C in the
absence of light for 1 h in a shaking incubator. Reactions were
terminated by the addition of 120 µl of 5% trichloroacetic acid
followed by a 2-h incubation at room temperature in the absence of
light to precipitate out all insoluble proteins. Samples were then
centrifuged for 5 min, and 60 µl of the supernatants was added to 400 µl of 500 mM Tris, pH 8.8, buffer and mixed thoroughly. A
250-µl aliquot of each solution was added to microtiter plate wells
and read in a fluorometer at an excitation wavelength of 485 nm and an
emission wavelength of 538 nm.
80 °C for 1-4 days.
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (37K):
[in a new window]
Fig. 1.
Lactacystin affects co- and
post-translational turnover of apoB in intact HepG2 cells.
A, nearly confluent cells were pulsed for 15 min with
35S protein labeling mix, and the radioactivity was chased
for 120 min. Lactacystin (LC; 25 µM) was added
to some dishes 60 min before the pulse and was included during both
pulse and chase periods. After the chase, medium was collected, and
cells were solubilized. Cell lysates were immunoprecipitated with
anti-apoB antibody, and the immunoprecipitates were analyzed by
SDS-PAGE and fluorography. B, the percentage of apoB
remaining after 60 and 120 min was assessed by determining the amount
of radioactivity in the apoB100 bands (recovered from media and lysates
of control and lactacystin-treated cells) as a percentage of the amount
recovered at 0 chase time (n = 3). Lactacystin (25 µM) was present at all steps of the pulse-chase protocol
including preincubation, pulse, and chase. Open circles,
without lactacystin; closed circles, with lactacystin.

View larger version (34K):
[in a new window]
Fig. 2.
In permeabilized HepG2 cells lactacystin
inhibits co-translational turnover of apoB but does not block
post-translational degradation of apoB or the generation of the 70-kDa
fragment. A, nearly confluent HepG2 cells were pulsed
for 15 min with 35S protein labeling mix, chased for 10 min, and permeabilized with digitonin, and permeabilized cells were
then incubated in CSK buffer. In some dishes, lactacystin (25 µM) was included in the preincubation medium, the pulse,
and the chase, as well as during the incubation of permeabilized cells
in CSK buffer. Permeabilized cells were solubilized and then
immunoprecipitated with a polyclonal anti-apoB antibody.
Immunoprecipitates were analyzed by SDS-PAGE and fluorography. The
arrowheads indicate the 550-kDa apoB100 and its 70 kDa
degradation intermediate. B, for the experiment in
A, the turnover of apoB in permeabilized cells in the
presence and absence of lactacystin was assessed by plotting the total
apoB radioactivity recovered (in the apoB100 bands) from permeabilized
cells at various times of incubation in CSK buffer (zero time, 60 min,
and 120 min). Lactacystin (LC) was present at all steps of
the pulse-chase protocol including preincubation, pulse, and chase.
Open circles, without lactacystin; closed
circles, with lactacystin.

View larger version (83K):
[in a new window]
Fig. 3.
Permeabilization of HepG2 cells does not
cause leakage of radiolabeled apoB into the surrounding medium.
Nearly confluent HepG2 cells were pulsed for 15 min with
35S protein labeling mix, chased for 10 min, and
permeabilized with digitonin (50 µg/ml, 10 min), and permeabilized
cells were incubated in CSK buffer for different times. Cells and CSK
buffer were immunoprecipitated for apoB, and immunoprecipitates were
analyzed by SDS-PAGE and fluorography. A, a representative
experiment showing the distribution of apoB100 and the 70-kDa fragment
in permeabilized cells and CSK buffer over a 2-h chase period;
C, a second representative experiment showing the
distribution of apoB in permeabilized cells and CSK buffer over a 3-h
chase period (0, 1, 2, and 3 h). B and D,
comparison of the amount of immunoprecipitable radiolabeled full-length
apoB detected in permeabilized cells (closed circles) and
the CSK buffer (open circles) for each incubation period
(mean ± S.D.) from experiments in A and C,
respectively.

View larger version (19K):
[in a new window]
Fig. 4.
Comparison of proteasomal activity in intact
and permeabilized cells using a fluorogenic protease assay. Nearly
confluent cells were preincubated in the presence or absence of
lactacystin (25 µM) for 60 min. Some cells were then
permeabilized, and others were left intact. All cells were then
collected in phosphate-buffered saline plus 0.1% Triton X-100,
homogenized 15× in a glass homogenizer, and centrifuged. Cell lysates
were then used in performing fluorogenic protease assays according to
modifications of Twining (29) with fluorescein isothiocyanate-labeled
casein as the proteolytic substrate. Following the 1-h incubation time,
samples were treated with 5% trichloroacetic acid to precipitate
insoluble proteins and centrifuged. Then 60 µl of the supernatant was
diluted with 400 µl of 500 mM Tris, pH 8.8, and read in a
Fluoroskan fluorescent spectrophotometer at an excitation wavelength of
485 nm and emission wavelength of 538 nm. A, comparison of
total proteolytic activity between intact (open bars) and
permeabilized cells (closed bars) (n = 4).
B, comparison of lactacystin-inhibitable protease activity
assessed by the difference in fluorescent units between control and
lactacystin-treated intact cells (open bars) and
permeabilized cells (closed bars).

View larger version (46K):
[in a new window]
Fig. 5.
Immunoblotting of the 20 S proteasomal
subunits in intact and permeabilized HepG2 cells. A,
cell lysates from the intact and permeabilized cells used in Fig. 4
were subjected to SDS-PAGE (10% (v/v) acrylamide resolving gel), and
proteins were then transferred overnight at 4 °C onto nitrocellulose
membranes. Membranes were blocked with a 5% solution of fat-free dry
milk powder. Immunoblotting was performed to detect 20 S proteasomal
subunits by using the primary antibody rabbit anti-rat 20 S proteasome
(1:1000 for 1 h) followed by the secondary antibody goat
anti-rabbit conjugated to peroxidase (1:8000 for 1 h). Membranes
were then incubated in an ECL detection reagent for 60 s and
exposed to Hyperfilm and developed. B, bands were
quantitated by densitometry, and the percentage of total 20 S subunits
was determined in comparison with that found in intact cells.
-Lactone, and ALLN--
We
compared the inhibitory effects of ALLN and lactacystin on
post-translational degradation of apoB in permeabilized cells. In
contrast to lactacystin, ALLN increased the amount of apoB remaining
after a 2-h chase (Fig. 6A).
The apoB remaining (as a percentage of total apoB at time 0) in
lactacystin-treated and ALLN-treated permeabilized cells was 30.7 ± 5.2% and 75.1 ± 6.7%, respectively (p < 0.05, n = 3). Thus, unlike lactacystin, ALLN appeared
to inhibit post-translational apoB degradation. In addition, ALLN also
inhibited the post-translational apoB fragmentation, which generates
the distinct apoB intermediates in permeabilized cells, including
the 70-kDa fragment (Fig. 6B).

View larger version (50K):
[in a new window]
Fig. 6.
Comparative effects of ALLN, lactacystin, and
clastolactacystin
-lactone. Nearly
confluent HepG2 cells were pulsed for 15 min with 35S
protein labeling mix, chased for 10 min, and permeabilized with
digitonin, and then permeabilized cells were incubated in CSK buffer.
Either lactacystin (25 µM) or ALLN (40 µg/ml) was
included in the preincubation medium, the pulse, and the chase, as well
as during the incubation of permeabilized cells in CSK buffer.
Permeabilized cells were solubilized and immunoprecipitated, and the
immunoprecipitates were analyzed by SDS-PAGE and fluorography.
A, the amount of radioactivity in the apoB100 bands was
quantitated by scintillation counting (n = 3).
Open bars, no inhibitors; dotted bars, with
lactacystin; closed bars, with ALLN. B, a
representative experiment is shown with arrowheads
indicating the 550-kDa apoB100 and its 70-kDa degradation intermediate.
C, effect of clastolactacystin
-lactone (10 µM) on the generation of the 70-kDa fragment
(n = 2) added either during the pulse or during the
chase.
-lactone,
the active species of the lactacystin inhibitor (34), to ensure that
the insensitivity of apoB fragmentation to lactacystin was not a result
of the inability of the inhibitor to convert to its active form in a
permeabilized cell. The addition of clastolactacystin
-lactone
either before or after permeabilization did not prevent the loss of
apoB in permeabilized cells, nor did it interfere with the appearance
of the 70-kDa fragment (Fig. 6C). Interestingly, the
addition of the inhibitor before the pulse resulted in an increase in
the abundance of the 70-kDa fragment, most likely as a result of an
increased initial pool of the full-length apoB from a diminished
co-translational degradation (Fig. 6C).

View larger version (62K):
[in a new window]
Fig. 7.
Effect of inhibition of MTP on apoB
fragmentation in permeabilized HepG2 cells. A, nearly
confluent HepG2 cells grown in six-well plates were incubated for
1 h with MTP inhibitor (10 nM) and ALLN (20 µg/ml).
Cells were then pulsed, chased for 10 min, and permeabilized. Control
and treated cells were then collected, with the remaining cells being
incubated in CSK buffer supplemented with or without the MTP inhibitor.
Cells were collected and solubilized, and 35S labeled apoB
was immunoprecipitated from solubilized cells and analyzed by SDS-PAGE
and fluorography as described under "Experimental Procedures." The
entire gel is shown, and the positions of the 550-kDa apoB and the
70-kDa fragment are indicated. The radioactivity associated with intact
apoB (B) and the 70-kDa fragment (C) was
quantitated by cutting and scintillation counting of the bands. The
results are given as the mean ± S.E. (n = 3).

View larger version (20K):
[in a new window]
Fig. 8.
The effect of MTP inhibition on generation of
the 70-kDa fragment in permeabilized cells is
dose-dependent. Nearly confluent HepG2 cells grown in
six-well plates were incubated for 1 h in methionine-free medium
containing 0-50 nM of the MTP inhibitor and 20 µg/ml
ALLN. Cells were pulsed, chased, permeabilized and incubated in CSK
according to the procedure described in the legend to Fig. 5. Cells
were solubilized, and 35S-labeled apoB was
immunoprecipitated from solubilized cells and analyzed by SDS-PAGE and
fluorography as described under "Experimental Procedures." The
radioactivity associated with the intact apoB (A) and the
70-kDa fragment (B) was quantitated by cutting and
scintillation counting of the bands. The results are given as the
mean ± S.E. (n = 3).

View larger version (101K):
[in a new window]
Fig. 9.
DTT alters the pattern of apoB fragmentation
in permeabilized cells. Nearly confluent HepG2 cells grown in
35-mm dishes were incubated for 1 h in methionine-free medium. 1 min prior to the pulse, cells were treated with 2 mM DTT.
Following the preincubation, cells were briefly pulsed with
35S protein labeling mix and chased for 10 min in
-MEM
plus 10 mM L-methionine and 5 mM
cysteine in the presence and absence of DTT. Cells were washed and
permeabilized with digitonin (50 µg/ml, 10 min). Control and treated
cells were then treated with 50 µl of iodoacetamide, incubated on ice
for 5 min, and harvested. The remaining cells were incubated in CSK
buffer supplemented with or without DTT and harvested as described
above following the 2-h incubation period. Harvested cells were
solubilized, and 35S-labeled apoB was immunoprecipitated
from solubilized cells and analyzed by SDS-PAGE and fluorography as
described under "Experimental Procedures." The entire gel is shown,
and the positions of the 550-kDa apoB and the 70-kDa fragment are
indicated.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
and Sec61
proteins of the translocon, whereby it becomes susceptible to
proteolytic degradation by the cytosolic proteasome. Thus, based on the
above reports and our present findings, it appears that the role of the
cytosolic proteasome may not be limited to the co-translational
degradation of newly synthesized apoB but that it may also be involved
in the degradation of apoB following both translation and translocation.
-lactone as well as a more general
inhibitor, ALLN. Interestingly, pretreatment with lactacystin caused an
increase in the pool of radiolabeled apoB that was fragmented in
permeabilized cells, resulting in an increase in the generation of the
70-kDa intermediate. In contrast to lactacystin, ALLN did inhibit the
generation of the 70-kDa fragment. ALLN is an inhibitor of calpains and
other ER cysteine proteases (36) and has also been shown to inhibit
proteasomal activity, however not as specifically as lactacystin or
clastolactacystin
-lactone, the most selective proteasome inhibitors
presently known (37-41). Hence, these data appear to suggest that apoB
fragmentation in permeabilized cells is independent of the proteasome
and may instead be dependent upon other ER cysteine protease(s). One
candidate is ER-60 protease, an ER-resident cysteine protease that has
been shown to be associated with apoB (42, 43). Such proteases may not
be limited only to apoB degradation in permeabilized cells but instead
may also participate in the post-translational degradation of apoB in
intact cells. In fact, post-translational degradation of apoB in intact cells was not completely inhibited in the presence of lactacystin. This
indicates that in addition to proteasome-mediated degradation of apoB,
an alternate degradation system may be involved in the post-translational turnover of apoB. It appears that this
non-proteasome-mediated degradation pathway can be unmasked following
permeabilization of these cells, resulting in the loss of functional
cytosolic proteasome.
| |
FOOTNOTES |
|---|
* This work was supported by Heart and Stroke Foundation of Ontario Grant T-3302 (to K. A.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Division of Clinical Biochemistry, DPLM, Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada. Tel.: 416-813-8682; Fax: 416-813-6257; E-mail: k.adeli@utoronto.ca.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: apoB, apolipoprotein B; ALLN, N-acetyl-leucyl-leucyl-norleucinal; CSK, cytoskeletal buffer; DTT, dithiothreitol; ER, endoplasmic reticulum; MTP, microsomal triglyceride transfer protein; PAGE, polyacrylamide gel electrophoresis; MEM, minimum essential medium; PIPES, 1,4-piperazinediethanesulfonic acid.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bostrom, K.,
Boren, J.,
Wettesten, M.,
Sjorberg, A.,
Bondjers, G.,
Wiklund, O.,
Carlsson, P.,
and Olofsson, S.-O.
(1988)
J. Biol. Chem.
263,
4434-4442 |
| 2. | Pullinger, C., North, J., Teng, B., Rifici, V. A., Ronhild de Brito, A. E., and Scott, J. (1989) J. Lipid Res. 30, 1065-1077[Abstract] |
| 3. | Dashti, N., Williams, D., and Alaupovic, P. (1989) J. Lipid Res. 30, 1365-1373[Abstract] |
| 4. | Moberly, J., Cole, T., Alpers, D. H., and Schonfeld, G. (1990) Biochim. Biophys. Acta 1042, 70-80[Medline] [Order article via Infotrieve] |
| 5. |
Davis, R. A.,
Thrift, R. N.,
Wu, C. C.,
and Howell, K. E.
(1990)
J. Biol. Chem.
265,
10005-10011 |
| 6. |
Thrift, R. N.,
Drisko, J.,
Dueland, S.,
Trawick, J. D.,
and Davis, R. A.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
9161-9165 |
| 7. |
Rusinol, A. E.,
Chan, E. Y. W.,
and Vance, J. E.
(1993)
J. Biol. Chem.
268,
25168-25175 |
| 8. |
Rusinol, A. E.,
and Vance, J. E.
(1995)
J. Biol. Chem.
270,
13318-13325 |
| 9. |
Bonnardel, J. A.,
and Davis, R. A.
(1995)
J. Biol. Chem.
270,
28892-28896 |
| 10. |
Boren, J.,
Graham, L.,
Wettesten, M.,
Scott, J.,
White, A.,
and Olofsson, S.-O.
(1992)
J. Biol. Chem.
267,
9858-9867 |
| 11. |
Cartwright, I. J.,
Hebbachi, A. M.,
and Higgins, J. A.
(1993)
J. Biol. Chem.
268,
20937-20952 |
| 12. | Yeung, S. J., Chen, S. H., and Chan, L. (1996) Biochemistry 35, 13843-13848[CrossRef][Medline] [Order article via Infotrieve] |
| 13. |
Fisher, E. A.,
Zhou, M.,
Mitchell, D. M.,
Wu, X.,
Omura, S.,
Wang, H.,
Goldberg, A. L.,
and Ginsberg, H. N.
(1997)
J. Biol. Chem.
272,
20427-20434 |
| 14. |
Wu, X.,
Sakata, N.,
Lele, K. M.,
Zhou, M.,
Jiang, H.,
and Ginsberg, H. N.
(1997)
J. Biol. Chem.
272,
11575-11580 |
| 15. |
Benoist, F.,
and Grand-Perret, T.
(1997)
J. Biol. Chem.
272,
20435-20442 |
| 16. |
Adeli, K.
(1994)
J. Biol. Chem.
269,
9166-9175 |
| 17. |
Sakata, N.,
Wu, X.,
Dixon, J. L.,
and Ginsberg, H. N.
(1993)
J. Biol. Chem.
268,
22967-22970 |
| 18. |
Chen, Y.,
Le Caherec, F.,
and Chuck, S. L.
(1998)
J. Biol. Chem.
273,
11887-11894 |
| 19. |
Mitchell, D. M.,
Zhou, M.,
Pariyarath, R.,
Wang, H.,
Aitchison, J. D.,
Ginsberg, H. N.,
and Fisher, E. A.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
14733-14738 |
| 20. |
Zhou, M.,
Fisher, E. A.,
and Ginsberg, H. N.
(1998)
J. Biol. Chem.
273,
24649-24653 |
| 21. |
Cavallo, D.,
McLeod, R. S.,
Rudy, D.,
Aiton, A.,
Yao, Z.,
and Adeli, K.
(1998)
J. Biol. Chem.
273,
33397-33405 |
| 22. |
Laio, W.,
Yeung, S.-C. J.,
and Chan, L.
(1998)
J. Biol. Chem.
273,
27225-27230 |
| 23. | Davis, R., Prewett, A., Thompson, J., Chan, P., Borchardt, R., and Gallaher, W. (1989) J. Lipid Res. 30, 1185-1196[Abstract] |
| 24. |
Furukawa, S.,
Sakata, N.,
Ginsberg, H. N.,
and Dixon, J. L.
(1992)
J. Biol. Chem.
267,
22630-22638 |
| 25. |
Wang, C.-N.,
Hobman, T. C.,
and Brindley, D. N.
(1995)
J. Biol. Chem.
270,
24924-24931 |
| 26. | Sparks, J. D., and Sparks, C. E. (1993) Curr. Opion. Lipidol. 4, 177-186 |
| 27. |
Verkade, H. J.,
Fast, D. G.,
Rusinol, A. E.,
Scraba, D. G.,
and Vance, D. E.
(1993)
J. Biol. Chem.
268,
24990-24996 |
| 28. |
Du, E. Z.,
Kurth, J.,
Wang, S. L.,
Humiston, P.,
and Davis, R. A.
(1994)
J. Biol. Chem.
269,
24169-24176 |
| 29. | Sallach, S., and Adeli, K. (1995) Biochim. Biophys. Acta 1265, 29-32[Medline] [Order article via Infotrieve] |
| 30. |
Adeli, K.,
Wettesten, M.,
Asp, L.,
Mohammadi, A.,
Macri, J.,
and Olofsson, S.-O.
(1997)
J. Biol. Chem.
272,
5031-5039 |
| 31. | Adeli, K., and Sinkevitch, C. (1990) FEBS Lett. 2, 345-348[CrossRef] |
| 32. | Twining, S. S. (1984) Anal. Biochem. 143, 30-34[CrossRef][Medline] [Order article via Infotrieve] |
| 33. | Laemmli, U. K. (1970) Nature 227, 680-685[CrossRef][Medline] [Order article via Infotrieve] |
| 34. |
Dick, L. R.,
Cruikshank, A. A.,
Destree, A. T.,
Grenier, L.,
McCormack, T. A.,
Melandri, F. D.,
Nunes, S. L.,
Palombia, V. J.,
Parent, L. A.,
Plamondon, L.,
and Stein, R. L.
(1997)
J. Biol. Chem.
272,
182-188 |
| 35. | Ginsberg, H. N. (1995) Curr. Opin. Lip. 6, 275-280 |
| 36. | Saski, T., Kishi, M., Saito, M., Tanaka, T., Higuchi, N., Kominami, E., Katunuma, N., and Murachi, T. (1990) J. Enzyme Inhib. 3, 195-201[Medline] [Order article via Infotrieve] |
| 37. | Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., and Goldberg, A. L. (1994) Cell 78, 761-771[CrossRef][Medline] [Order article via Infotrieve] |
| 38. |
Mellgran, R. L.
(1997)
J. Biol. Chem.
272,
29899-29903 |
| 39. | Coux, O., Tanaka, K., and Goldberg, A. L. (1996) Annu. Rev. Biochem 65, 801-847[CrossRef][Medline] [Order article via Infotrieve] |
| 40. |
Fenteany, G.,
Standaert, R. F.,
Lane, W. S.,
Choi, S.,
Corey, E. J.,
and Schreiber, S. L.
(1995)
Science
268,
726-731 |
| 41. |
Dick, L. R.,
Cruikshank, A. A.,
Grenier, L.,
Melandri, F. D.,
Nunes, S. L.,
and Stein, R. L.
(1996)
J. Biol. Chem.
271,
7273-7276 |
| 42. | Adeli, K., Mohammadi, A., Kito, M., Urade, R., and Macri, J. (1996) Circulation 94, I-149 |
| 43. |
Adeli, K.,
Macri, J.,
Mohammadi, A.,
Kito, M.,
Urade, R.,
and Cavallo, D.
(1997)
J. Biol. Chem.
272,
22489-22494 |
| 44. |
Macri, J.,
and Adeli, K.
(1997)
Arterioscler. Thromb.
17,
2982-2994 |
| 45. | Shelness, G. S., and Thornburg, J. T. (1996) J. Lipid Res. 37, 408-419[Abstract] |
| 46. | Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., and Riordon, J. R. (1995) Cell 83, 129-135[CrossRef][Medline] [Order article via Infotrieve] |
| 47. | Ward, C. L., Omura, S., and Kopito, R. R. (1995) Cell 83, 121-127[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
W. Qiu, R. K. Avramoglu, A. C. Rutledge, J. Tsai, and K. Adeli Mechanisms of glucosamine-induced suppression of the hepatic assembly and secretion of apolipoprotein B-100-containing lipoproteins J. Lipid Res., August 1, 2006; 47(8): 1749 - 1761. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ohsaki, J. Cheng, A. Fujita, T. Tokumoto, and T. Fujimoto Cytoplasmic Lipid Droplets Are Sites of Convergence of Proteasomal and Autophagic Degradation of Apolipoprotein B Mol. Biol. Cell, June 1, 2006; 17(6): 2674 - 2683. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Domitrovich, D. J. Felmlee, and A. Siddiqui Hepatitis C Virus Nonstructural Proteins Inhibit Apolipoprotein B100 Secretion J. Biol. Chem., December 2, 2005; 280(48): 39802 - 39808. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Qiu, R. Kohen-Avramoglu, S. Mhapsekar, J. Tsai, R. C. Austin, and K. Adeli Glucosamine-Induced Endoplasmic Reticulum Stress Promotes ApoB100 Degradation: Evidence for Grp78-Mediated Targeting to Proteasomal Degradation Arterioscler. Thromb. Vasc. Biol., March 1, 2005; 25(3): 571 - 577. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hevi and S. L. Chuck Ferritins Can Regulate the Secretion of Apolipoprotein B J. Biol. Chem., August 22, 2003; 278(34): 31924 - 31929. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Higashi, H. Itabe, H. Fukase, M. Mori, Y. Fujimoto, and T. Takano Transmembrane Lipid Transfer Is Crucial for Providing Neutral Lipids during Very Low Density Lipoprotein Assembly in Endoplasmic Reticulum J. Biol. Chem., June 6, 2003; 278(24): 21450 - 21458. [Abstract] |